Novo Nordisk A/S ADR NVO

$40.00 +0.86 (2.20%)

Valuation

Market cap
178,600,000,000
Revenue TTM
$46,792,290,000
Net income TTM
$15,508,510,000
P/E (trailing)
9.74
P/E (forward)
11.45
Profit margin
33.14%
Debt to equity
0.63

Trading

Volume
15,277,500
Avg volume
12,014,834
Day's range
$39.54 – $40.10
Shares out
4,465,000,000
Stochastic %K
95%
Beta
0.76
Analysts
Hold
Price target
$45.27

Price

Company profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare b...

Show more

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
45 44 44 88 88
Website
https://www.novonordisk.com
Address
Novo Alle 1, Bagsvaerd, Denmark

Latest news

Stocktwits

Jtlo Nov 1, 11:44 PM
$NVO 50 or stay in the house 30s You don’t deserve the 40s
0 replies
Lillyfee Nov 1, 10:23 PM
$NVO you should Buy Viking my guys
1 replies
GlobalTradersAcademy Nov 1, 9:28 PM
$NVO reports earnings soon, and options traders are bracing for a big move. Whether it beats that number, and in which direction, is what traders will be watching. Shares are up about 2% from a week ago, at their highest level in a month. $SPY $QQQ The breakdown covers the key price levels to watch. What's your read on $NVO here? Full story: https://globaltradersacademy.com/articles/novo-nordisk-earnings-options-market-bets-on-a-7-3-move-in-nvo?utm_source=stocktwits&utm_medium=social Free 14-day trial: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=NVO&tool=terminal
0 replies
YouVSYou Nov 1, 7:59 PM
$XOM for trend $GDYN for momentum $NVO needs confirmation $SCI needs repair All with unusual volume
2 replies
Mactd83 Nov 1, 4:49 PM
$NVO Denmark is about to have a massive move higher
1 replies
hogs1982 Nov 1, 3:27 AM
$NVO hate to say it but everyone I know is on peptides now for way cheaper and same glps.
1 replies
moneybag888 Nov 1, 3:15 AM
$NVO #FireTheCEO
0 replies
OnlyFibs Nov 1, 2:36 AM
$NVO 🚨 TESTING INSTITUTIONAL BUY ZONE | Q3 EARNINGS NOV 4 🚨$NVO is stabilizing inside its $38.00 – $39.50 Institutional Buy Zone on the 8H chart! Wegovy/Ozempic demand holds strong into earnings. 📊 CHART ZONES ($NVO, 8H): • Smart Money Sell: $49.00 – $51.50 • Institutional Sell: $46.00 – $48.00 • Institutional Buy: $38.00 – $39.50 (LOAD ZONE) • Smart Money Buy: $36.50 – $37.80 • Flow: $68K split on 01/27 $40C @ Ask 🎯 KEY LEVELS: 🐂 Bull Trigger: Hold $38.00 & reclaim $41.50 to target $46+. 🐻 Bear Trigger: 8H close below $36.50. BIAS: Tactical Dip-Buy off $38–$39.50 Demand 📊📈#hovdid
1 replies